E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Peripheral artery disease |
Enfermedad arterial períferica |
|
E.1.1.1 | Medical condition in easily understood language |
Claudication |
Claudicación |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10067825 |
E.1.2 | Term | Peripheral arterial disease |
E.1.2 | System Organ Class | 100000004866 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to compare the effect of long-term treatment with ticagrelor vs. clopidogrel on the event rate of the composite of CV death, MI and ischemic stroke in patients with established PAD. |
El objetivo principal del ensayo es comparar el efecto del tratamiento a largo plazo con ticagrelor en comparación con clopidogrel sobre la tasa de acontecimientos de la combinación de muerte cardiovascular (CV), infarto de miocardio (IM) e ictus isquémico (definido como cualquier ictus que no se haya demostrado que es fundamentalmente hemorrágico) en pacientes con enfermedad arterial periférica (EAP) demostrada |
|
E.2.2 | Secondary objectives of the trial |
To compare the effect of long-term treatment with ticagrelor vs. clopidogrel in patients with established PAD 1. Composite of CV death and MI 2. CV death 3. MI 4. All-cause mortality 5. Composite of CV death, MI, and all cause stroke 6. All revascularisation |
Comparar el efecto del tratamiento prolongado con ticagrelor en comparación con clopidogrel en pacientes con EAP establecida 1. Combinación de muerte CV e IM 2. Muerte CV 3. IM 4. La tasa de mortalidad por todas las causas 5. Combinación de muerte CV, IM e ictus de cualquier causa 6. Toda revascularización |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male and Female patients 50 years old or older 2. Symptomatic peripheral artery disease |
1.Hombres y mujeres de ?50 años 2. Enfermedad arterial periférica |
|
E.4 | Principal exclusion criteria |
1. Patients needing dual anti-platlet drug treatment before start of study 2. Planned revascularisation or amputation 3. Patients with known bleeding disorders 4. Patients with a history of intracranial bleed 5. Patients considered to be at risk of bradycardic events unless already treated with a permanent pacemaker |
1.Pacientes que precisan doble tratamiento antiagregante en el momento de la inclusión en el ensayo. 2.Revascularización o amputación programada 3. Pacientes con hemorragia sistemática. 4. Pacientes con Antecedentes de hemorragia intracraneal 5.Pacientes considerados de riesgo de episodios bradicárdicos salvo que se les haya implementado un marcapasos permanente |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Any event after randomization from the composite of cardiovascular death, myocardial infarction and ischemic stroke |
Cualquier acontecimiento por la combinación de muerte CV, IM e ictus isquémico, posterior a la aleatorización |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Up to approximately 37 months |
Aproximadamente 37 meses |
|
E.5.2 | Secondary end point(s) |
Composite of cardiovascular death and myocardial infarction after randomization. Cardiovascular death after randomization. Myocardial infarction after randomization. All-cause mortality after randomization. Cardiovascular death, myocardial infarction and all-cause stroke (ischaemic or haemorrhagic) after randomization. All revascularisation after randomization |
Combinación de Muerte cardiovascular e infarto de miocardio despues de la aletatorizacion. Muerte cardiovascular despues de la aletatorizacion. Infarto de miocardio despues de la aletatorizacion. Mortalidad por todas las causas despues de la aleatorizacion Muerte CV, IM e ictus de cualquier causa (isquémico o hemorrágico) despues de la aleatorizacion. Toda revascularización despues de la aleatorizacion. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Up to approximately 37 months |
Aproximadamente 37 meses |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 260 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Brazil |
Canada |
Chile |
China |
Japan |
Korea, Republic of |
Mexico |
Philippines |
Russian Federation |
Thailand |
Turkey |
Ukraine |
United States |
Vietnam |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Planned LSLV study completion date: 2016-01-07 |
Fecha planeada de la última visita del último paciente: 01-07-2016 |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |